These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 34856813)

  • 1. Comparison of amylase and lipase levels of patients with Type 2 diabetes under different treatment modalities.
    Cakmak R; Caklili OT; Tekin S; Hacisahinogullari H; Tanrikulu S; Koc MS; Dinccag N
    Biomark Med; 2022 Jan; 16(1):5-10. PubMed ID: 34856813
    [No Abstract]   [Full Text] [Related]  

  • 2. Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting.
    Lando HM; Alattar M; Dua AP
    Endocr Pract; 2012; 18(4):472-7. PubMed ID: 22440997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.
    Russell S
    Int J Clin Pharm; 2013 Apr; 35(2):159-72. PubMed ID: 23263796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incretins: their physiology and application in the treatment of diabetes mellitus.
    Tasyurek HM; Altunbas HA; Balci MK; Sanlioglu S
    Diabetes Metab Res Rev; 2014 Jul; 30(5):354-71. PubMed ID: 24989141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of biochemical parameters among DPP4 inhibitor users and other oral hypoglycaemic drug users: a cross-sectional study from Anuradhapura, Sri Lanka.
    Rathish D; Jayasumana C; Agampodi S
    J Health Popul Nutr; 2019 Jan; 38(1):3. PubMed ID: 30674350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incretin-based therapy in combination with basal insulin: a promising tactic for the treatment of type 2 diabetes.
    Vora J; Bain SC; Damci T; Dzida G; Hollander P; Meneghini LF; Ross SA
    Diabetes Metab; 2013 Feb; 39(1):6-15. PubMed ID: 23022130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of incretin-based therapies and sodium-glucose co-transporter-2 inhibitors as adjuncts to insulin therapy in Type 2 diabetes, with special reference to IDegLira.
    Wilding JP; Bain SC
    Diabet Med; 2016 Jul; 33(7):864-76. PubMed ID: 26525806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with DPP-4 inhibitors does not increase the chance of pancreatitis in patients with type 2 diabetes.
    Shetty AS; Nandith A; Snehalath C; Ramachandran A
    J Assoc Physicians India; 2013 Aug; 61(8):543-4. PubMed ID: 24818338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.
    Nauck MA; Kahle M; Baranov O; Deacon CF; Holst JJ
    Diabetes Obes Metab; 2017 Feb; 19(2):200-207. PubMed ID: 27709794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different glucagon effects during DPP-4 inhibition versus SGLT-2 inhibition in metformin-treated type 2 diabetes patients.
    Alsalim W; Persson M; Ahrén B
    Diabetes Obes Metab; 2018 Jul; 20(7):1652-1658. PubMed ID: 29498469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Change in glycated haemoglobin levels after initiating second-line therapy in type 2 diabetes: a primary care database study.
    Rathmann W; Bongaerts B; Kostev K
    Diabetes Obes Metab; 2016 Aug; 18(8):840-3. PubMed ID: 27062643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incretin-based drugs for type 2 diabetes: Focus on East Asian perspectives.
    Seino Y; Kuwata H; Yabe D
    J Diabetes Investig; 2016 Apr; 7 Suppl 1(Suppl 1):102-9. PubMed ID: 27186364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting.
    Garber AJ
    Am J Manag Care; 2010 Aug; 16(7 Suppl):S187-94. PubMed ID: 20809667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Managing postprandial glucose levels in patients with diabetes.
    Tenzer-Iglesias P; Brunton S
    J Fam Pract; 2008 Jan; 57(1 Suppl Managing):S17-24. PubMed ID: 18662529
    [No Abstract]   [Full Text] [Related]  

  • 16. Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies.
    Campbell RK; Cobble ME; Reid TS; Shomali ME
    J Fam Pract; 2010 Sep; 59(9 Suppl 1):S10-9. PubMed ID: 20824235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incretin mimetics and sodium-glucose co-transporter 2 inhibitors as monotherapy or add-on to metformin for treatment of type 2 diabetes: a systematic review and network meta-analysis.
    Jia S; Wang Z; Han R; Zhang Z; Li Y; Qin X; Zhao M; Xiang R; Yang J
    Acta Diabetol; 2021 Jan; 58(1):5-18. PubMed ID: 32514989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes.
    Davidson JA; Parente EB; Gross JL
    Arq Bras Endocrinol Metabol; 2008 Aug; 52(6):1039-49. PubMed ID: 18820816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative cardiovascular safety of glucagon-like peptide-1 receptor agonists versus other antidiabetic drugs in routine care: a cohort study.
    Patorno E; Everett BM; Goldfine AB; Glynn RJ; Liu J; Gopalakrishnan C; Kim SC
    Diabetes Obes Metab; 2016 Aug; 18(8):755-65. PubMed ID: 27003762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinguishing among incretin-based therapies. Patient education and self-management.
    Campbell RK; Cobble ME; Reid TS; Shomali ME
    J Fam Pract; 2010 Sep; 59(9 Suppl 1):S28-30. PubMed ID: 20824237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.